Myeloid cell-restricted insulin receptor deficiency protects against obesity-induced inflammation and systemic insulin resistance.
A major component of obesity-related insulin resistance is the establishment of a chronic inflammatory state with invasion of white adipose tissue by mononuclear cells. This results in the release of pro-inflammatory cytokines, which in turn leads to insulin resistance in target tissues such as skeletal muscle and liver. To determine the role of insulin action in macrophages and monocytes in obesity-associated insulin resistance, we conditionally inactivated the insulin receptor (IR) gene in myeloid lineage cells in mice (IR(Deltamyel)-mice). While these animals exhibit unaltered glucose metabolism on a normal diet, they are protected from the development of obesity-associated insulin resistance upon high fat feeding. Euglycemic, hyperinsulinemic clamp studies demonstrate that this results from decreased basal hepatic glucose production and from increased insulin-stimulated glucose disposal in skeletal muscle. Furthermore, IR(Deltamyel)-mice exhibit decreased concentrations of circulating tumor necrosis factor (TNF) alpha and thus reduced c-Jun N-terminal kinase (JNK) activity in skeletal muscle upon high fat feeding, reflecting a dramatic reduction of the chronic and systemic low-grade inflammatory state associated with obesity. This is paralleled by a reduced accumulation of macrophages in white adipose tissue due to a pronounced impairment of matrix metalloproteinase (MMP) 9 expression and activity in these cells. These data indicate that insulin action in myeloid cells plays an unexpected, critical role in the regulation of macrophage invasion into white adipose tissue and in the development of obesity-associated insulin resistance.
Mauer
Jan
J
Department of Mouse Genetics and Metabolism, Institute for Genetics, University of Cologne, Cologne, Germany.
Chaurasia
Bhagirath
B
Plum
Leona
L
Quast
Thomas
T
Hampel
Brigitte
B
Blüher
Matthias
M
Kolanus
Waldemar
W
Kahn
C Ronald
CR
Brüning
Jens C
JC
D000818:Animals; D002478:Cells, Cultured; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008099:Liver / Q000276:immunology; D008264:Macrophages / Q000276:immunology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009000:Monocytes / Q000276:immunology*; D018482:Muscle, Skeletal / Q000276:immunology; D009765:Obesity / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D011972:Receptor, Insulin / Q000235:genetics / Q000276:immunology*
D011972:Receptor, Insulin
Science. 1996 Feb 2;271(5249):665-8
8571133
J Biol Chem. 2001 May 4;276(18):14890-5
11278654
J Clin Invest. 1976 Nov;58(5):1123-35
993336
J Clin Invest. 2003 Dec;112(12):1785-8
14679172
Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1297-302
18216263
Mol Cell Endocrinol. 2009 Jan 27;298(1-2):25-32
18955107
J Clin Endocrinol Metab. 2003 Apr;88(4):1594-602
12679444
Nutr Metab Cardiovasc Dis. 2008 Sep;18(7):471-6
17976964
Mol Cell. 1998 Nov;2(5):559-69
9844629
Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83
10092513
FEBS Lett. 2009 Jan 22;583(2):293-300
19116150
Cell Biochem Funct. 1996 Mar;14(1):33-42
8907252
Nat Med. 2005 Feb;11(2):183-90
15685173
J Clin Invest. 2007 Jan;117(1):175-84
17200717
Cardiovasc Res. 2007 Mar 1;73(4):841-8
17234168
J Lipid Res. 2008 Sep;49(9):1894-903
18503031
Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10422-7
15240880
Cell Metab. 2006 Apr;3(4):247-56
16581002
Cell Metab. 2006 Apr;3(4):257-66
16581003
Biochem Biophys Res Commun. 2008 Jan 18;365(3):503-8
17999918
Nat Med. 2009 Aug;15(8):914-20
19633658
J Lipid Res. 2005 Nov;46(11):2347-55
16150820
N Engl J Med. 2001 Nov 8;345(19):1359-67
11794168
Nat Med. 2007 Apr;13(4):455-62
17351624
J Clin Endocrinol Metab. 2001 Jul;86(7):3257-65
11443198
J Clin Invest. 2003 Dec;112(12):1821-30
14679177
J Clin Invest. 1995 May;95(5):2111-9
7738178
Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33
17318226
J Surg Res. 2007 Dec;143(2):398-406
17583747
J Clin Invest. 1995 May;95(5):2409-15
7738205
Diabetes. 2008 Nov;57(11):2967-76
18728232
Am J Physiol Endocrinol Metab. 2001 May;280(5):E745-51
11287357
Biochem J. 1985 May 15;228(1):103-10
3890836
Crit Care Med. 2003 Feb;31(2):359-66
12576937
Science. 2001 Aug 31;293(5535):1673-7
11533494
Science. 2000 Sep 22;289(5487):2122-5
11000114
Nat Med. 2009 Aug;15(8):940-5
19633655
Obes Res. 2000 Dec;8(9):673-5
11225716
Science. 1993 Jan 1;259(5091):87-91
7678183
N Engl J Med. 2007 Apr 12;356(15):1517-26
17429083
J Biol Chem. 2001 Aug 31;276(35):32531-7
11443108
J Clin Invest. 2004 Feb;113(3):474-81
14755344
Cell Metab. 2008 Mar;7(3):236-48
18316029
Dev Cell. 2002 Jul;3(1):25-38
12110165
Transgenic Res. 1999 Aug;8(4):265-77
10621974
J Biol Chem. 2007 Nov 30;282(48):35279-92
17916553
J Clin Invest. 2008 Sep;118(9):3012-24
18677407
Nature. 2002 Nov 21;420(6913):333-6
12447443
Arterioscler Thromb Vasc Biol. 2002 Mar 1;22(3):380-6
11884278
Free Radic Biol Med. 2009 Apr 15;46(8):1058-67
19439231
Cell. 1997 Feb 21;88(4):561-72
9038347
Mol Cell. 2000 Jul;6(1):87-97
10949030
Int J Obes. 1989;13(5):603-12
2583914
Nat Med. 2005 Feb;11(2):191-8
15685170
Biochim Biophys Acta. 2005 Feb 14;1727(2):145-9
15716063
J Clin Invest. 2002 May;109(10):1321-6
12021247
J Clin Invest. 2003 Dec;112(12):1796-808
14679176
J Clin Invest. 2006 Jan;116(1):115-24
16341265
J Clin Invest. 2008 Jun;118(6):2132-47
18451994
J Clin Invest. 2000 Jan;105(2):199-205
10642598